FARMINGDALE, N.Y., April 26 Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced its attendance at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS), which was held in Orlando, FL, April 17-20, 2010, and is widely regarded as the premier educational wound care-focused program in the United States. Misonix exhibited and demonstrated its SonicOneŪ Ultrasonic Wound Cleansing and Debridement System to many of the over 2,100 clinicians in attendance.
As part of the educational program, over 100 clinical poster presentations were on display throughout the conference, 3 of which, were based on clinical applications of the SonicOne.
Martin Winkler, MD, FACS, of Bergan Mercy Hospital's Wound Center in Omaha, NE, demonstrated improved healing within shorter time spans. His poster was entitled "Aggressive Mechanical Bioburden Control Improves Wound Healing Rates: Liberal 22.5 kHz Ultrasonic Debridement Reduces Bioburden."
Elizabeth McElroy, MSN, CRNP, from The Center for Advanced Wound Care in Wyomissing, PA, presented "Evaluation of three new probes for use with an Ultrasonic Wound Care System in difficult to treat wounds." She utilized three new ultrasonic probes and identified additional clinical capabilities and uses for the SonicOne.
Frank Aviles, PT, CWS, WCC, FAACWS, Director of Therapy for a leading long term acute care facility in Natchitoches, LA, presented "Results of Ultrasound Assisted Wound Therapy on Complicated Patients to Promote Accelerated Proliferation of Granulation Tissue, Rapid Removal of Nonviable Tissue, and Managing Colonized Wounds." All cases focused on the clinical benefits of SonicOne; however, the most dramatic was represented by a patient facing physician recommended amputation of his foot, which was prevented following extended treatment with the SonicOne and resulted in preservation of his limb and maintenance of a normal lifestyle.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to demonstrate its commitment to the rapidly expanding wound care market by supporting important educational programs like SAWC/WHS," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Our wound care product platform, we believe, makes an important contribution to improving patient outcomes and we are gratified when data is presented by clinical experts that supports our investment in wound care research and development."
About Misonix: Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact: Kevin McGrath / Cameron Associates, Inc. 212-245-4577 Kevin@cameronassoc.com
SOURCE Misonix, Inc.